BiVictriX Interim results for the six months ended 30 June 2021
- Collaborations progressed with leading academic centres
- Further strengthening of intellectual property portfolio
- Successful Initial Public Offering (“IPO”) on AIM raising £7.5 million (gross) of new funding
- Highly experienced Board appointed
Alderley Park, 22 September 2021 BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces its maiden unaudited results for the six months ended 30 June 2021.